Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Agreement signed with Artemis Pharmaceuticals for transgenic mice
August 6th, 2004
Biovitrum AB and Artemis Pharmaceuticals GmbH, Cologne, have signed a research services agreement concerning the generation of RNAi-modified transgenic mice for the in vivo functional analysis of selected disease related genes. The application of RNAi based technologies for targeted knock-down of selected genes is one of the most promising methods for gene function analysis in basic and pharmaceutical research. There have only been limited studies showing utility of RNAi in corresponding mammalian organisms in vivo. Utilizing scientific methods developed in Artemis it is now possible to obtain an efficient, rapid and widespread RNAi knock down in adult transgenic...
Source: Genomics & Genetics Weekly (2004-08-06)
|
